CTLA4 and clear cell renal carcinoma: The aim of this review is to update on the relative efficacy of combined cabozantinib + nivolumab therapy with other immune checkpoint inhibitors combined with TKIs or monoclonal antibodies blocking the CTLA-4 for the first-line treatment of metastatic clear-cell renal cell carcinoma.